Article

Leucocyte antibodies in blood donors and a look back on recipients of their blood components

Institute of Haematology and Blood Transfusion, Warsaw, Poland.
Vox Sanguinis (Impact Factor: 3.3). 05/2007; 92(3):247-9. DOI: 10.1111/j.1423-0410.2007.00890.x
Source: PubMed

ABSTRACT The role of leucocyte antibodies in donors is poorly understood in pathogenesis of transfusion-related acute lung injury (TRALI). We examined antibodies in donors and traced recipients transfused with their blood components.
Antibodies were examined in 1043 donors by five methods, look back performed in 26 recipients.
Anti-human leucocyte antigen detected by enzyme-linked immunosorbent assay in 9.8% women but none in men. Specificities identified using FlowPRA, antibodies detected after several months. TRALI reported in one recipient from immunized donor. In 11 of 26 recipients without TRALI, cognate antigens were identified.
Detection of antibodies in donors cannot predict TRALI, even in recipients with cognate antigen(s).

Download full-text

Full-text

Available from: Jacek Nowak, Jun 30, 2015
0 Followers
 · 
113 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: One of the high-power limitations encountered in modern sonar systems is caused by the mutual interaction effect among the densely packed elements of projector arrays. This causes severe and complex effects at higher drive levels. This effect can be minimized by restructuring the array format with suitable selection of appropriate interelement spacing. The design considerations of uniform linear projector array formats that minimize the mutual interaction effect are presented. The radiation pattern and array gain of the proposed array are found to be improved, as far as certain signal and noise models are concerned
    Acoustics, Speech, and Signal Processing, 1988. ICASSP-88., 1988 International Conference on; 05/1988
  • [Show abstract] [Hide abstract]
    ABSTRACT: Transfusion-related acute lung injury (TRALI) is underdiagnosed and underreported. This is why we present cases suspected for TRALI, in which leucocyte antibodies were examined. We analysed 44 patients with respiratory insufficiency, related to transfusion, who met criteria of acute lung injury (ALI). Lymphocyte and granulocyte antibodies were examined in donors and patients by six methods. Based on recent trends, we divided patients into two groups: TRALI (without risk factors for ALI) and possible TRALI (with probable risk factors). The incidence of antibodies was 68.2%, the majority were human leucocyte antigen (HLA) class I and/or II, the minority were non-specific granulocyte antibodies; half of all detected antibodies, however, reacted with granulocytes. Antibodies were found in 17 donors (more often in TRALI than in possible TRALI) and in 19 patients (in four - suspected to be of the donor origin, which would diminish the number of antibodies to 15). In seven available cases, we observed cognate antigen and/or positive cross-match. In the majority of patients, TRALI occurred after transfusion of red cells, in 56.2%- stored above 14 days; all the units were non-leucoreduced. Lookback in two donors showed that transfusions in 20 patients did not result in reported TRALI, even in the patient with cognate antigen. Our clinical observations suggest that to distinguish between TRALI and possible TRALI is difficult and the results are equivocal - it is worth considering whether it can be omitted. We have confirmed that antibodies are involved in TRALI, although their role is very complex. The role of stored red blood cells in the development of TRALI requires further observations in comparison with a control group of patients without TRALI.
    Vox Sanguinis 08/2007; 93(1):70-7. DOI:10.1111/j.1423-0410.2007.00920.x · 3.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Several advances have been made in characterization of the molecule that carries human neutrophil antigen (HNA)-2a, NB1 glycoprotein, the gene that encodes NB1 glycoprotein, CD177, and the role of antibodies to HNA-2a in transfusion reactions. NB1 glycoprotein binds to the endothelial cell adhesion molecule, platelet endothelial cell adhesion molecule-1 (PECAM-1), and participates in neutrophil transmigration. The overexpression of neutrophil CD177 mRNA has become a useful, but nonspecific biomarker of myeloproliferative diseases, especially polycythemia vera. CD177 mRNA overexpression is also a biomarker of a subset of patients with essential thrombocythemia who are at increased risk of thromboembolic complications. In patients with myeloproliferative disorders CD177 mRNA overexpression is secondary to a gain-of-function mutation in JAK2, JAK2 V617F. NB1 glycoprotein is co-localized on neutrophil plasma membranes with proteinase 3 and a complex of NB1 glycoprotein and proteinase 3 may initiate the activation of neutrophils by antineutrophil cytoplasmic antibodies in patients with Wegener's granulomatosis. The inadvertent transfusion of antibodies to HNA-2a with blood components frequently causes pulmonary transfusion reactions. The expression of CD177 is an important biomarker of myeloproliferative diseases, NB1 glycoprotein is a ligand for PECAM-1 and it may have a role in Wegener's granulomatosis, and antibodies to HNA-2a frequently cause pulmonary transfusion reactions.
    Current Opinion in Hematology 12/2007; 14(6):688-93. DOI:10.1097/MOH.0b013e3282efed9e · 4.05 Impact Factor